The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.

Moderna's cancer vaccine has shown promising early results in Phase 3 trials, but the true measure of its success will be its ability to prevent cancer recurrence over the long term rather than outperforming existing treatments like Keytruda. This focus on sustained efficacy is crucial because many cancer treatments, while effective in the short term, often fail to keep the disease at bay over time. The implications of this research could be significant, potentially offering a new, long-term solution to cancer management if the vaccine can deliver on its promise.